Semaglutide kidney protection– True or Illusion?

1. What is Semaglutide?

Semaglutide kidney protection, Semaglutide is a GLP-1 (Glucagon-Like Peptide-1) receptor agonist originally developed for type 2 diabetes treatment. However, recent clinical trials indicate that it may also have cardiovascular and kidney-protective benefits, drawing significant attention in nephrology and endocrinology.

Common semaglutide-based medications include Ozempic and Wegovy, widely prescribed for both diabetes management and obesity treatment.

2. Semaglutide’s Kidney Protective Effects: Scientific Evidence

The FLOW (Evaluate Renal Function With Semaglutide Once Weekly) trial investigated semaglutide’s impact on chronic kidney disease progression in diabetic patients. The key findings were:

✅ Reduced Risk of Kidney Failure

Semaglutide reduced the risk of kidney failure by 24%
Hazard ratio (HR): 0.76 (95% CI: 0.66–0.88, p = 0.0003)

✅ Slower Decline in eGFR (Estimated Glomerular Filtration Rate)

Placebo group: -3.36 ml/min/1.73㎡ per year
Semaglutide group: -2.19 ml/min/1.73㎡ per year

✅ Significant Weight Loss Observed

Average weight reduction of 4.1 kg (95% CI: 3.65–4.56 kg)

These results suggest that semaglutide may not only regulate blood sugar but also help slow kidney function decline.

3. Controversy: Is Kidney Protection an Illusion Caused by Weight Loss?

While these findings are promising, some researchers question whether semaglutide’s renal benefits are truly independent of its weight loss effects.

🔹 Weight Loss Can Artificially Improve eGFR Readings

Losing weight can temporarily increase eGFR measurements, making kidney function appear better than it actually is.
Thus, the reported improvements in eGFR might not reflect actual kidney protection but rather a calculation artifact.

🔹 The Study Did Not Fully Account for Weight Loss Effects

Since semaglutide induces weight loss, it is crucial to determine if kidney protection persists after adjusting for weight loss effects.
Further analysis is needed to separate true renal benefits from weight-related changes.

4. Future Research Directions and Key Questions

1️⃣ Does semaglutide’s kidney protection occur independently of weight loss?
➡️ Further studies should analyze kidney function changes after adjusting for weight loss effects.

2️⃣ How can we rule out weight-related measurement biases?
➡️ Researchers should compare kidney function data before and after removing body surface area indexing from eGFR calculations.

3️⃣ Do non-obese patients experience the same kidney benefits?
➡️ If semaglutide truly protects the kidneys, its benefits should also be observed in patients without obesity.

5. Could Semaglutide Become a Kidney Protection Therapy?

At present, semaglutide shows strong potential as a kidney-protective agent. However, further studies are essential to confirm whether its benefits are genuine or mainly driven by weight loss.

📌 What We Know So Far
✔️ Semaglutide may reduce the risk of kidney failure.
✔️ It slows eGFR decline in patients with CKD.
✔️ Weight loss might play a significant role in the observed benefits.

📌 Remaining Uncertainties
⚠️ eGFR improvements may be overestimated due to weight loss effects.
⚠️ More research is needed to confirm benefits in non-obese individuals.
⚠️ Long-term studies should evaluate true kidney protection beyond weight effects.

Conclusion: Semaglutide kidney protection?

Semaglutide presents exciting possibilities for kidney protection, but additional studies must clarify whether its effects are direct or weight loss-related. As research progresses, we will gain deeper insights into its true potential in CKD management.

The Risks and Management of Hypertension: If Family History

Health for All